P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

BACKGROUND: Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial. Our objective was to compare the safety and efficacy of clopidogrel to ticagrelor and prasu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachdeva, Amit, Mutyala, Ratnabhushan, Mantri, Neha, Zhu, Shiyun, McNulty, Edward, Solomon, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224789/
https://www.ncbi.nlm.nih.gov/pubmed/37251366
http://dx.doi.org/10.1155/2023/1147352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224789/
https://www.ncbi.nlm.nih.gov/pubmed/37251366
http://dx.doi.org/10.1155/2023/1147352

Ejemplares similares